DeepAI
Log In Sign Up

A bayesian reanalysis of the phase III aducanumab (ADU) trial

07/08/2021
by   Tommaso Costa, et al.
0

In this article we have conducted a reanalysis of the phase III aducanumab (ADU) summary statistics announced by Biogen, in particular the result of the Clinical Dementia Rating-Sum of Boxes (CDR-SB). The results showed that the evidence on the efficacy of the drug is very low and a more clearer view of the results of clinical trials are presented in the Bayesian framework that can be useful for future development and research in the field.

READ FULL TEXT

page 4

page 5

page 7

02/04/2021

Improving the assessment of the probability of success in late stage drug development

There are several steps to confirming the safety and efficacy of a new m...
10/18/2021

Bayesian Persuasion in Sequential Trials

We consider a Bayesian persuasion or information design problem where th...
09/27/2022

Phases of methodological research in biostatistics - building the evidence base for new methods

Although the biostatistical scientific literature publishes new methods ...
06/01/2018

Adversity Index for Clinical Trials: An Inclusive Approach for Analysis of Safety Data

This paper proposes a new method for analysis of adverse event data in c...
02/21/2019

Towards More Flexible False Positive Control in Phase III Randomized Clinical Trials

Phase III randomized clinical trials play a monumentally critical role i...
02/13/2021

Towards reliable and transparent vaccine phase III trials with smart contracts

Transforming a vaccine concept into a real vaccine product is a complica...
10/12/2020

Predicting Clinical Trial Results by Implicit Evidence Integration

Clinical trials provide essential guidance for practicing Evidence-Based...